Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer

被引：3
|
作者：
Vos, Hanne [1 ,2 ]
Lambein, Kathleen [1 ,2 ]
Richard, Francois [3 ]
Marien, Bram [1 ,2 ]
Nevelsteen, Ines [1 ,2 ,4 ]
Punie, Kevin [4 ,5 ]
Wildiers, Hans [4 ,5 ]
Berben, Lieze [5 ]
Laenen, Annouschka [6 ]
Floris, Giuseppe [4 ,7 ]
Desmedt, Christine [3 ]
Smeets, Ann [1 ,2 ,4 ]
机构：
[1] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Surg Oncol, Leuven, Belgium
[2] Katholieke Univ Leuven, Dept Oncol, Leuven, Belgium
[3] Katholieke Univ Leuven, Lab Translat Breast Canc Res, Dept Oncol, Leuven, Belgium
[4] Univ Hosp Leuven, Multidisciplinary Breast Ctr, Leuven, Belgium
[5] Katholieke Univ Leuven, Dept Gen Med Oncol, Lab Expt Oncol, Univ Hosp Leuven, Leuven, Belgium
[6] Katholieke Univ Leuven, Leuven Biostat & Stat Bioinformat Ctr L BioStat, Leuven, Belgium
[7] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Imaging & Pathol, Lab Translat Cell & Tissue Res, Leuven, Belgium
来源：
NPJ BREAST CANCER | 2021年 / 7卷 / 01期
基金：
欧洲研究理事会;
关键词：
INFILTRATING LYMPHOCYTES; FREE SURVIVAL; TRASTUZUMAB;
D O I：
10.1038/s41523-021-00332-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The vast majority of studies investigating immune checkpoint inhibition (ICI) in patients with breast cancer have focused on triple-negative breast cancer (TNBC). In this study, we compared the tumor immune microenvironment (TIME) between TNBC and hormone receptor-negative HER2-positive breast cancer based on a selection of immune markers at the protein level in an institutional retrospective series. Additionally, we performed a similar comparison using publicly available transcriptomics data. Altogether, the results show a comparable TIME in both groups, with possible implications for the use of ICI in patients with hormone receptor-negative HER2-positive breast tumors.
引用
收藏
页数：5
相关论文
共 50 条
  • [21] DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer
    Debien, Veronique
    Adam, Virginie
    Coart, Elisabeth
    Agostinetto, Elisa
    Goulioti, Theodora
    Molinelli, Chiara
    Arahmani, Amal
    Zoppoli, Gabriele
    Piccart, Martine
    [J]. FUTURE ONCOLOGY, 2023, 19 (24) : 1655 - 1667
  • [22] Prognostic Significance of Single Progesterone Receptor Positivity A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer
    Fan, Ying
    Ding, Xiaoyan
    Xu, Binghe
    Ma, Fei
    Yuan, Peng
    Wang, Jiayu
    Zhang, Pin
    Li, Qing
    Luo, Yang
    [J]. MEDICINE, 2015, 94 (46) : e2066
  • [23] Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer
    Hoon, Siao-Nge
    Lau, Peter K. H.
    White, Alison M.
    Bulsara, Max K.
    Banks, Patricia D.
    Redfern, Andrew D.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (05):
  • [24] Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer
    Marks, Douglas K.
    Gartrell, Robyn D.
    El Asmar, Margueritta
    Boboila, Shuobo
    Hart, Thomas
    Lu, Yan
    Pan, Qingfei
    Yu, Jiyang
    Hibshoosh, Hanina
    Guo, Hua
    Andreopoulou, Eleni
    Wiechmann, Lisa
    Crew, Katherine
    Sparano, Joseph
    Hershman, Dawn
    Connolly, Eileen
    Saenger, Yvonne
    Kalinsky, Kevin
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10
  • [25] Benefits of capecitabine in hormone receptor-positive compared to hormone receptor-negative HER2 normal metastatic breast cancer
    Altundag, Kadri
    [J]. MEDICAL ONCOLOGY, 2024, 41 (06)
  • [26] Comparison of EndoPredict and MammaPrint in hormone receptor positive, HER2 negative breast cancer
    Boesl, A.
    Spitzmueller, A.
    Haid, A.
    Jasarevic, Z.
    Baruschke, K.
    Jaeger, S.
    Offner, F.
    [J]. BREAST, 2015, 24 : S46 - S47
  • [27] Updates in HER2-Positive and Triple-Negative Breast Cancers
    Telli, Melinda L.
    Gradishar, William J.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (5.5): : 605 - 609
  • [28] PIK3CA mutations in primary HER2-positive and triple negative breast cancer.
    Loibl, Sibylle
    Denkert, Carsten
    Loi, Sherene
    Andre, Fabrice
    Mueller, Berit
    Schneeweiss, Andreas
    Blohmer, Jens U.
    Jackisch, Christian
    Guo Sanxing
    Gade, Stephan
    Fasching, Peter A.
    Schem, Christian
    Sotiriou, Christos
    Untch, Michael
    Von Minckwitz, Gunter
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] Would 1.0 cm be a more suitable cutoff to subdivide pT1 tumors in hormone receptor-negative and HER2-positive breast cancer?
    Wang, Changjun
    Zhou, Yidong
    Zhu, Hanjiang
    Huang, Wei
    Chen, Ziyuan
    Mao, Feng
    Lin, Yan
    Zhang, Xiaohui
    Shen, Songjie
    Zhong, Ying
    Li, Yan
    Sun, Qiang
    [J]. CANCER MEDICINE, 2018, 7 (11): : 5420 - 5430
  • [30] Differential immune microenvironments in triple-negative breast cancer and hormone receptor-positive HER2-negative breast cancer: A spatial analysis via multiplex immunofluorescence
    Cha, Yoon Jin
    Park, Inho
    Shin, Su-Jin
    [J]. CANCER RESEARCH, 2024, 84 (06)
12345